Group items tagged

A new report has highlighted that the public places a higher value on medicines for severe medical conditions, such as terminal cancer, than the thresholds currently used by the National Institute for Health and Care Excellence (NICE). The study, conducted by the Office of Health Economics (OHE), found a misalignment between NICE's current 'severity modifier'-which determines whether a medicine is recommended for coverage on the National Health Service (NHS)-and the UK public's preference for prioritising health gains for more severe diseases. The research, commissioned and funded by the Association of the British Pharmaceutical Industry (ABPI), also indicated that the public is willing to pay more for medicines used to treat patients with severe disease. Titled 'Understanding Societal Preferences for Priority by Disease Severity in England and Wales,' the report suggested that NICE's current severity modifier may be limiting access to innovative treatments for NHS patients. The ABPI has called on the government and NICE to adopt a more flexible approach when assessing medicines for severe conditions.

On the occasion of World Sepsis Day, PAGB, the consumer healthcare association, has underscored the significant role that over-the-counter (OTC) antiseptics can play in preventing sepsis, potentially saving the NHS millions of pounds each year. Sepsis is a life-threatening condition where the body's immune system overreacts to an infection, causing damage to tissues and organs. Early recognition and treatment are crucial, as sepsis can rapidly escalate without prompt care. Symptoms of sepsis include confusion or slurred speech, fever, severe breathlessness, blotchy or mottled skin, and a lack of urination. PAGB emphasised that using OTC medicines early on can help prevent infections from worsening and potentially leading to serious conditions like sepsis. Michelle Riddalls, CEO of PAGB, stated: "Early prevention is always the best treatment for conditions that could potentially lead to sepsis. "If you don't get the right care for sepsis quickly it can be life-threatening so it's essential to seek immediate help if you or someone else has any symptoms.

Insect bites and stings typically increase in the summer in England. This year, however, there's been an earlier-than-usual spike in the number of people seeking NHS advice on the condition. According to the NHS England, visits to its insect bites and stings web page have nearly tripled in the last three weeks compared to the same period last year, peaking at an average of one visit every 22 seconds in the past week. Over the span of 21 days, a total of 68,986 visited the page, marking a significant 162 per cent increase compared to the 26,368 visits recorded in the first three weeks of May 2023. Although insect bites or stings are usually not serious and people tend to get better after a few days, the health service has cautioned that they can lead to infection or severe allergic reactions. People are encouraged to refer to the NHS website for advice or visit their local pharmacy to get advice and treatment for common health conditions, including infected insect bites.

A comprehensive cohort study has shed light on the benefits and risks associated with weight-loss drugs, offering valuable insights for clinical care and future research. Published in Nature Medicine on 20 January 2024, the study found the use of glucagon-like peptide 1 receptor agonists (GLP-1RAs)-used to treat diabetes and obesity-associated with a reduced risk of substance use disorders (including alcohol, cannabis, opioid and stimulant use disorders). Weight-loss drug use was also linked to decreased risks of psychotic disorders, seizures, neurocognitive disorders (including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses and several respiratory conditions. However, the use of GLP-1RAs was not without risks, as researchers identified an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic conditions, nephrolithiasis, interstitial nephritis, and drug-induced pancreatitis associated with their use. The analysis, utilising the U.S. Department of Veterans Affairs databases, compared 215,970 GLP-1 RA users with patients using sulphonylureas (n=159,465), DPP4 inhibitors (n=117,989), SGLT2 inhibitors (n=258,614), or a composite of the three (n=536,068).

To maximise the benefits of the Pharmacy First service for patients, the NHS, and community pharmacies, Community Pharmacy England (CPE) has advised the community pharmacists to to establish a robust relationship between community pharmacies and local general practices. The news comes after several reports highlighted issues regarding GP referrals for the seven minor ailment conditions under the Pharmacy First services. According to the reports, many pharmacists claimed that "many GPs in England are not sending patients to them to be treated - and that some are refusing to participate at all in the "groundbreaking" Pharmacy First scheme". In response to foster better relationship with the GPs, CPE has said that strong local collaborations will enable general practice teams to confidently refer patients to the Pharmacy First and other community pharmacy services where appropriate. Moreover, the organisation emphasised implementation of long-term changes in practice will take time. The current focus on integrating GP referrals to Pharmacy First will likely require sustained effort over several months or longer.

Long appointment wait times, embarrassment, and lack of trust are causing thousands of Brits to avoid visiting doctors, according to new research by Newfoundland Diagnostics. With 1 in 4 individuals resorting to A&E due to the lack of available GP appointments, which adds to the NHS burden, the medical self-testing brand believes that educating the nation on at-home testing can help ease the strain on the health service. The research revealed the top five reasons why Brits avoid visiting doctors for medical testing: Appointments taking too long to book (28 per cent) Embarrassment around their illnesses (15 per cent) Preference for at-home testing (12 per cent) Not having time (10 per cent) Lack of trust in the NHS or their GP (7 per cent) The research team cautioned that delaying care can worsen conditions, resulting in more severe cases that place greater strain on the NHS.

As Know Your Numbers! Week (2-8 September) kicks off, the NHS England is encouraging people in the East Midlands to get their blood pressure checked to prevent heart attacks and strokes. The residents can get their blood pressure checked at several places, including their local pharmacies. The initiative, part of a global campaign, highlights the crucial role of monitoring blood pressure, especially for those aged 40 and over. It is recommended that all adults aged 40 or over have their blood pressure tested at least every five years. High blood pressure or hypertension affects about a third of adults in the UK and is a major risk factor for cardiovascular disease (CVD), which is one of the leading causes of death in England. This condition often has no noticeable symptoms, but if untreated, it can result in serious health problems such as heart attacks and strokes. Local pharmacies play a crucial role in this health campaign, enabling individuals to monitor their risk of cardiovascular disease without needing an appointment. The NHS community pharmacy blood pressure check service has delivered more than a million checks nationally in the past year.

The National Institute for Health and Care Excellence (NICE) has made a new recommendation in its final guidance this week that could benefit almost 30,000 adults suffering from moderate to severe symptoms of uterine fibroids. The Department of Health and Social Care's executive non-departmental public body, NICE, has recommended linzagolix, also known as Yselty by Theramex to treat uterine fibroids. Linzagolix is recommended for use as a longer-term treatment (more than 6 months) and is not for people who need short-term treatment, for example, before planned uterine fibroid surgery. According to Jonathan Benger, NICE's Chief Medical Officer and Deputy Chief Executive, expressed his approval of the new recommendation, stating, " What makes Linzagolix particularly noteworthy is its flexibility; it can be taken either with or without hormone therapy. "This means that clinicians can now offer a more personalised approach to care, tailoring treatment to the specific needs and circumstances of each patient. "For many women, this will represent a significant improvement in managing this often challenging and distressing condition."

The National Institute for Health and Care Excellence (NICE) has recommended elafibranor 80mg tablets (marketed as IQIRVO) for treating primary biliary cholangitis (PBC), a rare liver disease. Developed by Ipsen, IQIRVO is the first medicine for PBC approved for use on the NHS in nearly a decade. Elafibranor is indicated for use in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA, or as monotherapy for those who cannot tolerate UDCA. PBC is a lifelong condition that can worsen over time if inadequately treated, potentially leading to liver failure, the need for a liver transplant, or, in rare instances, premature death. Approximately 25,000 people in the UK are affected by PBC-90 per cent of whom are women. Early-stage PBC patients often suffer from severe fatigue and a persistent, debilitating itch known as pruritus.

Researchers at the University of Oxford have received a grant of up to £600,000 from Cancer Research UK to develop the world's first vaccine to prevent ovarian cancer. Named OvarianVax, the innovative vaccine aims to train the immune system to recognise and attack the earliest stages of ovarian cancer. Ovarian cancer is the sixth most common cancer among women in the UK, with approximately 7,500 new cases diagnosed annually-equating to about 21 cases each day. It is also a leading cause of cancer-related deaths in women, with around 4,100 deaths each year, accounting for five per cent of all cancer deaths in UK females. Projections suggest that by 2038-2040, there could be around 9,400 new cases of ovarian cancer annually in the UK. Several factors influence a person's risk of developing ovarian cancer, including age, genetics, hormone replacement therapy (HRT), smoking, asbestos exposure, medical conditions such as endometriosis or diabetes, and obesity. Faults in the inherited genes, particularly BRCA1 and BRCA2, are linked to a higher risk of ovarian cancer, contributing to 5-15 per cent of cases.

Major health, care and research bodies, including the Department of Health and Social Care and the Office for National Statistics, should establish a national health data service in England to improve patient care and research - an NHS-commissioned review has recommended. Professor Cathie Sudlow's independent review of the UK health data landscape concluded that "complex and inefficient" data systems prevent and delay crucial analysis of health conditions affecting millions of people across the UK. The review - 'Uniting the UK's health data: a huge opportunity for society', published on 8 November 2024 - stressed the need for coordinated action across multiple organisations and stakeholders to ensure the greatest benefits for patients and the public from health-relevant data. They identified several barriers to using health data for public benefit and set our five recommendations for overcoming these barriers and transforming the national health data ecosystem. These include the establishment of a national health data service for England, embedded within existing organisational structures but with accountable senior leadership and a ring-fenced budget. Professor Sudlow said: "We are simply not maximising the benefits to society from the rich abundance of health data in the UK.

At the recent 'Locum Matters' online event held on June 25, 2024, members of the Pharmacists' Defence Association (PDA) discussed critical issues facing locum pharmacists, with a disturbing trend taking center stage: employers pressuring locum pharmacists to accept lower rates under the threat of potential pharmacy closures. The event, organised in response to feedback from PDA locum members, addressed a range of significant topics including training for the recent Pharmacy First Services, respect for professional autonomy, and the need for adequate rest breaks. However, the issue of rate pressure and pharmacy closures was a focal point. Several locum pharmacists reported that some employers were leveraging the possibility of pharmacy closures to coerce them into working for lower pay. This unethical practice has raised alarm within the locum community, highlighting the precarious working conditions many face.

The Community Pharmacy Walk-In Consultation Service (WICS), offering treatment for various minor ailments, recorded 19,567 consultations in 2024. This marks a 61 per cent increase compared to the 12,138 consultations recorded in 2023, according to data released by Community Pharmacy Cornwall (CPC) and obtained by The Pharmaceutical Journal. Launched in community pharmacies across Cornwall and the Isles of Scilly in January 2021, the minor ailment scheme is commissioned by the NHS and CPC. It enables locally accredited community pharmacists to supply prescription-only-medicines (POMs) for the treatment of several common conditions utilising patient group directions (PGDs) that Pharmacy First does not currently cover. These include vaginal candidiasis (vaginal thrush), dermatitis, migraine, conjunctivitis, and emergency hormonal contraception. Since its launch, the service has facilitated over 38,000 consultations, with 80 per cent of them resulting in advice or treatment that concluded the consultation in the pharmacy. WICS data also indicates that the service has helped avoid an estimated 30,000 GP appointments and more than 500 inappropriate A&E visits since its inception.